ライフサイエンスコーパス: posttraumatic stress disorder

1 s (i.e., general anxiety, depression, and/or posttraumatic stress disorder).

2 cessing (EMDR) is an effective treatment for posttraumatic stress disorder.

3 ess-related disorders, including anxiety and posttraumatic stress disorder.

4 oraphobia, obsessive-compulsive disorder, or posttraumatic stress disorder.

5 ical populations, with a particular focus on posttraumatic stress disorder.

6 ive disorders including major depression and posttraumatic stress disorder.

7 hods for primary prevention and treatment of posttraumatic stress disorder.

8 onditions such as autism, schizophrenia, and posttraumatic stress disorder.

9 disrupted in psychiatric conditions such as posttraumatic stress disorder.

10 depressant for major depressive disorder and posttraumatic stress disorder.

11 qual to 35, indicating a high probability of posttraumatic stress disorder.

12 ium and symptoms of anxiety, depression, and posttraumatic stress disorder.

13 rium and symptoms of anxiety, depression, or posttraumatic stress disorder.

14 vant to spatial memory deficits described in posttraumatic stress disorder.

15 of Event Scale 15 item measuring symptoms of posttraumatic stress disorder.

16 illnesses like major depressive disorder and posttraumatic stress disorder.

17 spatial memory dysfunction in, for example, posttraumatic stress disorder.

18 ychiatric conditions, such as depression and posttraumatic stress disorder.

19 tion regulation in insomnia, depression, and posttraumatic stress disorder.

20 ric conditions such as anxiety disorders and posttraumatic stress disorder.

21 nt of the patients showed a delayed onset of posttraumatic stress disorder.

22 riencing symptoms commensurate with clinical posttraumatic stress disorder.

23 to psychiatric disorders such as anxiety or posttraumatic stress disorder.

24 , including generalized anxiety disorder and posttraumatic stress disorder.

25 eveloping this drug class as a treatment for posttraumatic stress disorder.

26 illnesses, such as depression, anxiety, and posttraumatic stress disorder.

27 per 100 for hypertension to 0.6 per 100 for posttraumatic stress disorder.

28 e therapy in the clinic for the treatment of posttraumatic stress disorder.

29 ors report long-term psychologic symptoms of posttraumatic stress disorder.

30 on on emotional behavior in a mouse model of posttraumatic stress disorder.

31 understand black women's heightened risk for posttraumatic stress disorder.

32 conferences and showed reduced prevalence of posttraumatic stress disorder (45% vs 69%; p = 0.01), an

33 ence letters may even increase prevalence of posttraumatic stress disorder (52.4% vs 37.1%; p = 0.03)

34 , 20.2%; generalized anxiety disorder, 7.9%; posttraumatic stress disorder, 9.8%; alcohol dependence,

35 specific psychiatric disorders (depression, posttraumatic stress disorder, addiction, social anxiety

36 ich remained significant after adjusting for posttraumatic stress disorder (adjusted RR = 1.34, 95% c

37 hose who screened positive for depression or posttraumatic stress disorder after return from deployme

38 s (i.e., sex of the exposed parent, parental posttraumatic stress disorder, age at Holocaust exposure

39 rove health-related quality of life, but not posttraumatic stress disorder among ICU survivors and ma

40 r among ICU survivors and may result in less posttraumatic stress disorder among relatives of ICU pat

41 Posttraumatic stress disorder, an area of large unmet me

42 New possibilities for treating posttraumatic stress disorder and anxiety disorders invo

43 pite significant overlap of symptoms between posttraumatic stress disorder and anxiety disorders, the

44 es an updated review of sleep disturbance in posttraumatic stress disorder and anxiety-related disord

45 elin signaling may enhance susceptibility to posttraumatic stress disorder and comorbid conditions su

46 thasone compared with placebo on symptoms of posttraumatic stress disorder and depression and health-

47 nts, beneficial effects on the occurrence of posttraumatic stress disorder and depression may be pres

48 Posttraumatic stress disorder and depression were presen

49 nea and insomnia), mental health status (eg, posttraumatic stress disorder and depression), nonocular

50 e blast TBI was also observed on measures of posttraumatic stress disorder and depression.

51 ively or negatively affect the prevalence of posttraumatic stress disorder and depression.

52 stoperative admission to the ICU may lead to posttraumatic stress disorder and depression.

53 by deficient neurosteroidogenesis, including posttraumatic stress disorder and major depressive disor

54 es in connectivity in patients with comorbid posttraumatic stress disorder and MDD.

55 a burden to daily life and characteristic of posttraumatic stress disorder and other anxiety disorder

56 responses and have been have been linked to posttraumatic stress disorder and other mental health af

57 le target in developing novel treatments for posttraumatic stress disorder and related disorders.

58 erapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders and to evaluate whether a

59 pulsive disorder, major depressive disorder, posttraumatic stress disorder, and addiction.

60 target for treatment of depression, anxiety, posttraumatic stress disorder, and also against age-rela

61 chronic symptoms of postconcussive disorder, posttraumatic stress disorder, and depression and for th

62 ast 6-month generalized anxiety disorder and posttraumatic stress disorder, and past 12-month alcohol

63 tions, such as generalized anxiety disorder, posttraumatic stress disorder, and social anxiety disord

64 d chemotherapy-related cognitive impairment, posttraumatic stress disorder, and traumatic brain injur

65 may have high levels of anxiety, depression, posttraumatic stress disorders, and/or complicated grief

66 l comorbid psychiatric conditions, including posttraumatic stress disorder, anxiety disorders, obsess

67 Mental disorders (any disorder, mood, posttraumatic stress disorder, anxiety, alcohol use diso

68 Depression, posttraumatic stress disorder, anxiety, suicidal ideatio

69 s potential therapeutic effects for treating posttraumatic stress disorder are related to altering em

70 %, 42%, and 24% for depression, anxiety, and posttraumatic stress disorder) at 6 and 12 months.

71 hopathology (indiscriminate social behavior, posttraumatic stress disorder, attention-deficit/hyperac

72 ive disorders (mean scores >35), followed by posttraumatic stress disorder, borderline personality di

73 ocial outcomes (depression, anxiety, stress, posttraumatic stress disorder, burden, activity restrict

74 -year anxiety disorders, mood disorders, and posttraumatic stress disorder by sexual identity (hetero

75 of traumatic events is a hallmark symptom of posttraumatic stress disorder, characterized by rich and

76 ew Version (PSS-I) and the stressor-specific Posttraumatic Stress Disorder Checklist (PCL-S); seconda

77 oms of posttraumatic stress (measured by the Posttraumatic Stress Disorder Checklist [PCL]), personal

78 outcomes were posttraumatic stress symptoms (Posttraumatic Stress Disorder Checklist for DSM-5), func

79 onnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist).

80 s 6 months after patient discharge using the Posttraumatic Stress Disorder Checklist-Civilian Version

81 y was assessed at hospital discharge via the Posttraumatic Stress Disorder Checklist-Specific scale;

82 ck women experienced higher risk of lifetime posttraumatic stress disorder compared with white women.

83 Symptoms of posttraumatic stress disorder, depression, and health-re

84 antify the impact of psychiatric conditions (posttraumatic stress disorder, depression, anxiety, and

85 ty disorders, obsessive-compulsive disorder, posttraumatic stress disorder, depressive disorders, bip

86 ses including mild traumatic brain injury or posttraumatic stress disorder display alterations on ASL

87 Intelligence was not associated with posttraumatic stress disorder, eating disorders, and anx

88 rders, such as major depressive disorder and posttraumatic stress disorder, exact enormous socioecono

89 Secondary outcomes included posttraumatic stress disorder experienced by the family

90 conversely, to the potential development of posttraumatic stress disorder following trauma.

91 entia among men with stress disorders except posttraumatic stress disorder, for which women had a hig

92 The Psychiatric Genomics Consortium-Posttraumatic Stress Disorder group (PGC-PTSD) combined

93 co-occurring psychiatric conditions and with posttraumatic stress disorder having the largest impact.

94 in-angiotensin system has been implicated in posttraumatic stress disorder; however, the mechanisms r

95 polymorphism, rs4523957, is associated with posttraumatic stress disorder in humans, consistent with

96 that PACAP dysregulation is associated with posttraumatic stress disorder in humans.

97 health, increasing depression, anxiety, and posttraumatic stress disorder in these same villages.

98 ld higher prevalence of major depressive and posttraumatic stress disorders in women compared with me

99 he Impact of Event Scale was the most common posttraumatic stress disorder instrument.

100 Posttraumatic stress disorder is often comorbid with MDD

101 erapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders is unclear.

102 younger, have more obesity, depression, and posttraumatic stress disorder, less obstructive coronary

103 Posttraumatic stress disorder manifests after exposure t

104 he primary symptoms linked to deployment are posttraumatic stress disorder, mood disorders, GI proble

105 nisms of severe sepsis in the development of posttraumatic stress disorder need further examination.

106 roup analysis revealed a lower prevalence of posttraumatic stress disorder (odds ratio, 0.23; 95% CI,

107 nd 78 patients (13.8%) who received placebo (posttraumatic stress disorder: odds ratio, 0.82; 95% CI,

108 y a role in the formation and persistence of posttraumatic stress disorder, of which sleep impairment

109 There has been relatively little study of posttraumatic stress disorder or obsessive-compulsive di

110 02), bipolar I (OR, 1.5; 95% CI, 1.06-2.05), posttraumatic stress disorder (OR, 1.6; 95% CI, 1.27-2.1

111 nalyses used a priori seeds relevant to TMS, posttraumatic stress disorder, or MDD (subgenual anterio

112 yment (depression: OR, 1.4; 95% CI, 1.1-1.9; posttraumatic stress disorder: OR, 2.4; 95% CI, 2.1-2.8)

113 ntify anxiety, stress, caregiver burden, and posttraumatic stress disorder outcomes in informal careg

114 of threat.SIGNIFICANCE STATEMENT Anxiety and posttraumatic stress disorder patients generalize fear t

115 In psychiatric disorders such as posttraumatic stress disorder, PFC hyperactivity is asso

116 ant-reported MVC characteristics with 8-week posttraumatic stress disorder (PTSD) adjusting for pre-M

117 s the prevalence of anxiety, depression, and posttraumatic stress disorder (PTSD) after injury and th

118 earlier trauma exposure is known to predict posttraumatic stress disorder (PTSD) after subsequent tr

119 f exposure to stressful experiences, such as posttraumatic stress disorder (PTSD) and depression, are

120 an drive neuropsychiatric disorders, such as posttraumatic stress disorder (PTSD) and drug addiction.

121 ales disproportionately have higher rates of posttraumatic stress disorder (PTSD) and experience grea

122 ibitory avoidance-based "2-hit" rat model of posttraumatic stress disorder (PTSD) and identified pred

123 orders with hyperarousal symptoms, including posttraumatic stress disorder (PTSD) and major depressio

124 tress reactivity is a predominant feature of posttraumatic stress disorder (PTSD) and may reflect dis

125 ticipants (N=558) were assessed for probable posttraumatic stress disorder (PTSD) and probable depres

126 ticipants (N=558) were assessed for probable posttraumatic stress disorder (PTSD) and probable depres

127 associated memories is relevant for treating posttraumatic stress disorder (PTSD) and related syndrom

128 ical systems are altered in association with posttraumatic stress disorder (PTSD) and resilience.

129 ration (FDA) as "breakthrough therapies" for posttraumatic stress disorder (PTSD) and treatment-resis

130 s), obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD) are common mental d

131 e biomarkers of the presence and severity of posttraumatic stress disorder (PTSD) are elusive, yet ba

132 Patients with posttraumatic stress disorder (PTSD) are hyperresponsive

133 tudies have found that those who suffer from posttraumatic stress disorder (PTSD) are more likely to

134 d was a significant risk for a high level of posttraumatic stress disorder (PTSD) arousal symptoms.

135 We prospectively examined posttraumatic stress disorder (PTSD) as a long-term cons

136 Early life trauma (ELT) exposure and posttraumatic stress disorder (PTSD) both affect neural

137 lex traumatic events are at risk of not only posttraumatic stress disorder (PTSD) but also other ment

138 Posttraumatic stress disorder (PTSD) co-occurs with subs

139 e resilient to psychiatric disorders such as posttraumatic stress disorder (PTSD) compared with those

140 The risk of posttraumatic stress disorder (PTSD) following trauma is

141 Posttraumatic stress disorder (PTSD) has been associated

142 The limited neurobiological understanding of posttraumatic stress disorder (PTSD) has been partially

143 Posttraumatic stress disorder (PTSD) has been shown to b

144 Posttraumatic stress disorder (PTSD) has increasingly be

145 ncreasing predictability of animal models of posttraumatic stress disorder (PTSD) has required active

146 or (alpha1AR) antagonist prazosin for combat posttraumatic stress disorder (PTSD) in 67 active duty s

147 Posttraumatic stress disorder (PTSD) in adolescents is c

148 lable from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of t

149 the neurobiological mechanisms that predict posttraumatic stress disorder (PTSD) in recent trauma su

150 re to stress is a risk factor for developing posttraumatic stress disorder (PTSD) in response to trau

151 al blood during the onset and development of posttraumatic stress disorder (PTSD) indicate widespread

152 Posttraumatic stress disorder (PTSD) is a common psychia

153 Posttraumatic stress disorder (PTSD) is a common psychia

154 Posttraumatic stress disorder (PTSD) is a common, freque

155 Posttraumatic stress disorder (PTSD) is a debilitating d

156 Posttraumatic stress disorder (PTSD) is a debilitating p

157 Posttraumatic stress disorder (PTSD) is a disabling psyc

158 Posttraumatic stress disorder (PTSD) is a frequent anxie

159 Posttraumatic stress disorder (PTSD) is a heterogeneous

160 Posttraumatic stress disorder (PTSD) is a highly prevale

161 Posttraumatic stress disorder (PTSD) is a prevalent and

162 Posttraumatic stress disorder (PTSD) is a prevalent, ser

163 Posttraumatic stress disorder (PTSD) is a psychiatric il

164 Posttraumatic stress disorder (PTSD) is a relatively com

165 Posttraumatic stress disorder (PTSD) is a severe anxiety

166 Posttraumatic stress disorder (PTSD) is a stress disorde

167 Posttraumatic stress disorder (PTSD) is associated with

168 Posttraumatic stress disorder (PTSD) is both a prevalent

169 econsolidation marker.SIGNIFICANCE STATEMENT Posttraumatic stress disorder (PTSD) is characterized by

170 Posttraumatic stress disorder (PTSD) is considered a dis

171 In the aftermath of a disaster, the risk of posttraumatic stress disorder (PTSD) is high.

172 The development of posttraumatic stress disorder (PTSD) is influenced by ge

173 Posttraumatic stress disorder (PTSD) is linked to elevat

174 Posttraumatic stress disorder (PTSD) is prevalent, persi

175 Although posttraumatic stress disorder (PTSD) is well studied amo

176 We therefore postulated that posttraumatic stress disorder (PTSD) may be associated w

177 Posttraumatic stress disorder (PTSD) may contribute to h

178 Posttraumatic stress disorder (PTSD) may develop when me

179 ived from genome-wide association studies of posttraumatic stress disorder (PTSD) may inform risk for

180 ly described the paradoxical co-existence in posttraumatic stress disorder (PTSD) of sensory intrusiv

181 interactions between smoking and symptoms of posttraumatic stress disorder (PTSD) on pain intensity,

182 Medication and psychotherapy treatments for posttraumatic stress disorder (PTSD) provide insufficien

183 The neural substrates of pediatric posttraumatic stress disorder (PTSD) remain incompletely

184 Studies of posttraumatic stress disorder (PTSD) report volume abnor

185 nced trauma and associated distress-that is, posttraumatic stress disorder (PTSD) severity-more than

186 Studies on posttraumatic stress disorder (PTSD) showing attentional

187 dicate a prevalence for clinically important posttraumatic stress disorder (PTSD) symptoms of 25%.

188 intensive care unit (ICU) might reduce their posttraumatic stress disorder (PTSD) symptoms.

189 The efficacy of posttraumatic stress disorder (PTSD) treatments in psych

190 in white matter organization in people with posttraumatic stress disorder (PTSD) using diffusion MRI

191 The prevalence of posttraumatic stress disorder (PTSD) was 31.46% (95% CI

192 s process a potential therapeutic target for posttraumatic stress disorder (PTSD), a mental illness c

193 y of daily living, 20% screened positive for posttraumatic stress disorder (PTSD), all SF-12 physical

194 of NPY with trauma-evoked syndromes such as posttraumatic stress disorder (PTSD), although the exact

195 Hippocampus atrophy is implicated in posttraumatic stress disorder (PTSD), and may partly ref

196 ent among veterans, especially veterans with posttraumatic stress disorder (PTSD), and poses a major

197 sychiatric disorders, such as depression and posttraumatic stress disorder (PTSD), are inadequate.

198 posure therapy is an effective treatment for posttraumatic stress disorder (PTSD), but a comprehensiv

199 smaller hippocampal and amygdala volumes in posttraumatic stress disorder (PTSD), but findings have

200 psychotherapy is a first-line treatment for posttraumatic stress disorder (PTSD), but its mechanisms

201 posure therapy is an effective treatment for posttraumatic stress disorder (PTSD), but many patients

202 to underlie the pathophysiology of pediatric posttraumatic stress disorder (PTSD), but the few studie

203 al patterns of spontaneous brain activity in posttraumatic stress disorder (PTSD), but the findings a

204 r (GR) sensitivity is present in people with posttraumatic stress disorder (PTSD), but the molecular

205 hippocampal volume is frequently observed in posttraumatic stress disorder (PTSD), but the psychologi

206 n array of pathological conditions including posttraumatic stress disorder (PTSD), characterized by d

207 ism rs9315202 and psychopathology, including posttraumatic stress disorder (PTSD), depression, and al

208 cumented heightened systemic inflammation in posttraumatic stress disorder (PTSD), few studies have a

209 d C-reactive protein, have been described in posttraumatic stress disorder (PTSD), generalized anxiet

210 erapy (CPT), an evidence-based treatment for posttraumatic stress disorder (PTSD), has not been teste

211 stress and stress-related disorders, such as posttraumatic stress disorder (PTSD), is a prominent exa

212 e genetic basis of three disorder categories-posttraumatic stress disorder (PTSD), major depressive d

213 est were 30-day prevalence postdeployment of posttraumatic stress disorder (PTSD), major depressive e

214 eneralization of fear, a cardinal feature of posttraumatic stress disorder (PTSD), manifests as inapp

215 re-based therapy, an effective treatment for posttraumatic stress disorder (PTSD), relies on extincti

216 In about 30-50% of patients with posttraumatic stress disorder (PTSD), symptoms persist a

217 or stress-related psychopathologies, such as posttraumatic stress disorder (PTSD), that are character

218 factor for cardiovascular disease (CVD), and posttraumatic stress disorder (PTSD), the sentinel stres

219 for developing anxiety disorders, including posttraumatic stress disorder (PTSD), the underlying mec

220 e well-known peripheral immune activation in posttraumatic stress disorder (PTSD), there are no studi

221 tion to threat is perturbed in patients with posttraumatic stress disorder (PTSD), with some studies

222 Posttraumatic stress disorder (PTSD)-a chronic, debilita

223 tress develop over time into the syndrome of posttraumatic stress disorder (PTSD).

224 y few preventive interventions available for posttraumatic stress disorder (PTSD).

225 insufficient to reduce the burden of chronic posttraumatic stress disorder (PTSD).

226 ences, including their propensity to develop posttraumatic stress disorder (PTSD).

227 is widely accepted as a pathogenic marker of posttraumatic stress disorder (PTSD).

228 emory processes, and to risk and symptoms of posttraumatic stress disorder (PTSD).

229 g in the formation of indelible memories and posttraumatic stress disorder (PTSD).

230 the risk of stress-related disorders such as posttraumatic stress disorder (PTSD).

231 identified a role of leaky neuronal RyR2 in posttraumatic stress disorder (PTSD).

232 tric disorders, and is a defining feature of posttraumatic stress disorder (PTSD).

233 f quetiapine monotherapy in the treatment of posttraumatic stress disorder (PTSD).

234 s modulatory transmitter, is associated with posttraumatic stress disorder (PTSD).

235 nimal model of traumatic memory formation in posttraumatic stress disorder (PTSD).

236 n considered imperative in psychotherapy for posttraumatic stress disorder (PTSD).

237 onfer an increased incidence and severity of posttraumatic stress disorder (PTSD).

238 ce to existing evidence-based treatments for posttraumatic stress disorder (PTSD).

239 stress during a traumatic event may lead to posttraumatic stress disorder (PTSD).

240 e variability (HRV) has been associated with posttraumatic stress disorder (PTSD).

241 d to trauma and may be at increased risk for posttraumatic stress disorder (PTSD).

242 d its dysfunction potentially contributes to posttraumatic stress disorder (PTSD).

243 ity to neuropsychiatric disorders, including posttraumatic stress disorder (PTSD).

244 ith histories of childhood abuse and current posttraumatic stress disorder (PTSD).

245 depressive symptoms, prior head injury, and posttraumatic stress disorder (PTSD).

246 ndividuals either resilient or vulnerable to posttraumatic stress disorder (PTSD).

247 exposure and sertraline for the treatment of posttraumatic stress disorder (PTSD).

248 c nausea and prospective risk for developing posttraumatic stress disorder (PTSD).

249 g fear- and trauma-related disorders such as posttraumatic stress disorder (PTSD).

250 e development of mental disorders, including posttraumatic stress disorder (PTSD).

251 ala reactivity is a vulnerability factor for posttraumatic stress disorder (PTSD); however, our under

252 sing a locally validated version of the UCLA Posttraumatic Stress Disorder Reaction Index (range, 0-4

253 of targeting the renin-angiotensin system in posttraumatic stress disorder remain unknown.

254 (mood, anxiety, substance use, personality, posttraumatic stress disorder, schizophrenia, and psycho

255 (OR, 1.15; 95% CI, 1.02-1.30; P = .02), and posttraumatic stress disorder score (OR, 1.04; 95% CI, 1

256 fied between overall DE symptom severity and posttraumatic stress disorder scores and tear breakup ti

257 Five anxiety disorders were included: posttraumatic stress disorder, social anxiety disorder,

258 uman postmortem datasets from depression and posttraumatic stress disorder studies have identified ma

259 suicidal plan, bipolar disorder, psychosis, posttraumatic stress disorder, substance dependence, cur

260 ation manual was associated with significant posttraumatic stress disorder symptom reduction at 2 mon

261 ent negative life events, and depressive and posttraumatic-stress-disorder symptom scores with placen

262 Posttraumatic stress disorder symptomatology is common a

263 An in-person posttraumatic stress disorder symptomatology was assesse

264 e pooled prevalences of clinically important posttraumatic stress disorder symptoms (95% CI) were 25%

265 rlson index of zero) had higher frequency of posttraumatic stress disorder symptoms (adjusted odds ra

266 rrest and subsequent hospitalization-induced posttraumatic stress disorder symptoms (cardiac arrest-i

267 ationship to whole-brain cortical thickness, posttraumatic stress disorder symptoms (PTSD) and depres

268 The prevalence of long-term posttraumatic stress disorder symptoms among family memb

269 patient- and family-member risk factors for posttraumatic stress disorder symptoms among family memb

270 turned out to be a significant predictor of posttraumatic stress disorder symptoms at 3-month follow

271 atients with general anxiety, depression, or posttraumatic stress disorder symptoms during 2-year fol

272 lihood of remission from general anxiety and posttraumatic stress disorder symptoms during follow-up.

273 e individuals, increased lifetime stress and posttraumatic stress disorder symptoms explained the maj

274 ICU risk factors for posttraumatic stress disorder symptoms included benzodia

275 Family member risk factors for posttraumatic stress disorder symptoms included preexist

276 Clinically important posttraumatic stress disorder symptoms occurred in one f

277 studies reported significant improvement in posttraumatic stress disorder symptoms of relatives of I

278 rathreshold general anxiety, depression, and posttraumatic stress disorder symptoms ranged from 38% t

279 ore was 17 (9-24), and pooled prevalences of posttraumatic stress disorder symptoms were 17% (10-26%)

280 Posttraumatic stress disorder symptoms were associated w

281 Posttraumatic stress disorder symptoms were higher in th

282 Posttraumatic stress disorder symptoms were present in 3

283 found no significant reduction in patients' posttraumatic stress disorder symptoms with ICU diaries

284 vised (scores >/= 1.6 indicating substantial posttraumatic stress disorder symptoms).

285 s associated with a significant reduction in posttraumatic stress disorder symptoms, 2) a self-help r

286 The primary outcome was posttraumatic stress disorder symptoms, and secondary ou

287 significant general anxiety, depression, or posttraumatic stress disorder symptoms, and these sympto

288 r depression symptoms and may have increased posttraumatic stress disorder symptoms.

289 subsequent remission of general anxiety and posttraumatic stress disorder symptoms.

290 urse-led ICU follow-up clinic did not reduce posttraumatic stress disorder symptoms.

291 ess severity were not associated with family posttraumatic stress disorder symptoms.

292 y healthy patients are at increased risk for posttraumatic stress disorder symptoms.

293 acotherapies and device-based treatments for posttraumatic stress disorder that have been developed v

294 memories underlie anxiety disorders, such as posttraumatic stress disorder, the key neural and molecu

295 Posttraumatic stress disorder was assessed by the Short

296 Acute stress disorder and posttraumatic stress disorder were diagnosed according t

297 lthough symptoms of anxiety, depression, and posttraumatic stress disorder were found to be common 1

298 ental Disorders (version IV) Criterion A for posttraumatic stress disorder were interviewed.

299 h symptom levels of depression, anxiety, and posttraumatic stress disorder, which are strongly associ

300 , bipolar disorder, depression, anxiety, and posttraumatic stress disorder) with major CVD outcomes (